Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila has maintained an Overweight rating on Zymeworks (NASDAQ:ZYME) and increased the price target from $12 to $14.
March 12, 2024 | 11:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Derek Archila has reaffirmed an Overweight rating on Zymeworks and raised the price target from $12 to $14.
The increase in price target by a reputable analyst like Derek Archila suggests a positive outlook on Zymeworks' stock, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100